(Sirukumab) - 药物靶点：IL-6_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Shirukumabu、Sirukumab (genetical recombination) (JAN)、Sirukumab (USAN)

+ [3]

靶点

IL-6

作用机制

IL-6抑制剂(白细胞介素-6抑制剂)

治疗领域

免疫系统疾病神经系统疾病心血管疾病+ [5]

在研适应症-

非在研适应症

哮喘新型冠状病毒感染重度抑郁症+ [6]

原研机构

GSK Plc

在研机构-

非在研机构

Janssen Research & Development LLC

GSK PlcCentocor Research & Development, Inc.

+ [3]

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

序列信息

Sequence Code 9909244H

来源: *****

Sequence Code 9909249L

来源: *****

关联

21

项与 Sirukumab 相关的临床试验

NCT04380961 / Completed临床2期

Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical COVID-19 Disease

The purpose of this study is to evaluate the clinical response of sirukumab (administered as a single intravenous dose) plus standard of care (SOC) compared to placebo plus SOC in COVID-19.

开始日期2020-04-24

申办/合作机构

Janssen Pharmaceutica NV

NCT02899026 / Withdrawn临床3期

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in Subjects With Polymyalgia Rheumatica

Sirukumab is a human anti-IL-6 monoclonal antibody that selectively binds to the cytokine with high affinity that may have therapeutic benefit in the treatment of polymyalgia rheumatica (PMR) by interrupting multiple pathogenic pathways. Sirukumab inhibits IL-6-mediated signal transducer and activator of transcription 3 (STAT3) phosphorylation, resulting in the inhibition of the biological effect of IL-6. This study will evaluate the efficacy and safety of sirukumab to characterize the benefit-to-risk profile of sirukumab in the treatment of active PMR. The study will be conducted in 2 parts (Part A and Part B) and consists of the following phases: Screening phase, Part A: 52-week double-blind treatment phase, Part B: 52-week extension phase with no study drug administration and a 16-week follow-up phase if applicable.
Approximately 150 subjects with a diagnosis of PMR and active disease within 6 weeks of baseline will be randomized into Part A, the 52-week double-blind treatment phase, to receive one of two doses of sirukumab or placebo, each in addition to a pre-specified prednisone taper. The efficacy and safety of sirukumab in sustaining remission will be assessed at Week 52. Subjects completing Part A of the study who are in clinical remission will be eligible to enter Part B, the 52-week extension phase, designed to investigate the long-term maintenance of remission and safety following cessation of sirukumab treatment and to assess long-term corticosteroid use. Subjects will need to have follow-up safety evaluations for at least 16 weeks after receiving the last dose of study drug, applicable for those who have withdrawn prematurely from the study or who have completed Part A but are not eligible for Part B.

开始日期2018-03-15

申办/合作机构

GSK Plc

NCT02794519 / Withdrawn临床2期

205076: A Phase II, Multicenter, Randomized, Double-blind (Sponsor-unblind), Placebo- Controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of Sirukumab in Subjects With Severe, Poorly Controlled Asthma

Sirukumab is a fully human anti interleukin (IL)-6 immunoglobulin G1-kappa monoclonal antibody (MAb) which is in development for the treatment of rheumatoid arthritis (RA). The continuing unmet need in subjects with asthma refractory to corticosteroid therapy and increased understanding of asthma pathogenesis have stimulated the development of targeted biologics based on predictive biomarkers. The majority of approaches to date have targeted T Helper 2 (Th2) cytokines or their downstream effects. Targeting IL-6 in severe asthma represents an unprecedented approach that has potential to address non-Th2 drivers of severe asthma. This multicenter, randomized, double-blind (sponsor-unblind), placebo-controlled, parallel group study will investigate the efficacy of sirukumab compared to placebo in subjects having uncontrolled severe asthma despite use of high dose inhaled corticosteroid (ICS) in combination with long-acting Beta-agonist (LABA). The study will employ a variable treatment period for individual subjects. Dosing will continue every 4 weeks until week 44 (inclusive), or until 24 weeks after the final subject has been randomized, whichever the sooner. Upon receiving the final dose of study medicine or placebo, subjects will enter a 16 week Follow Up period. Overall, the duration of participation for subjects who complete the full 44-week treatment period and Follow Up period may be up to 64 weeks. Approximately 175 subjects will be randomized such that 140 evaluable subjects complete the study.

开始日期2016-09-23

申办/合作机构

GSK Plc

100 项与 Sirukumab 相关的临床结果

登录后查看更多信息

100 项与 Sirukumab 相关的转化医学

登录后查看更多信息

100 项与 Sirukumab 相关的专利（医药）

登录后查看更多信息

78

项与 Sirukumab 相关的文献（医药）

2024-01-01·BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned?

Review

作者: Feist, Eugen ; Burmester, Gerd R ; Avci, Ali Berkant

The use of different pathways in the treatment of rheumatoid arthritis has led to a significant decrease in the number of treatment-resistant patients. In this context, interleukin (IL)-6 inhibition has filled an important gap in rheumatoid arthritis treatment with its effectiveness and safety in both monotherapy and combinations. The process of IL-6 inhibition initiated with IL-6 receptor blockers has prompted questions regarding the potential impact and safety of different inhibitions of this pathway, such as the direct blockade of IL-6. Following the termination of the development of sirukumab because of mortality data in early studies, the investigation of olokizumab, which targets a different region of the IL-6 cytokine, has renewed the hope in this area and the safety concerns have been largely alleviated by the open-label extension data. In addition, the efficacy and safety of tocilizumab and sarilumab have led to a rapid investigation of biosimilars and new potent IL-6 receptor blockers. A comprehensive understanding of mechanisms of this pathway with further long-term clinical data and basic research may provide a decisive impact on selecting the appropriate mechanism as the first choice in personalized treatments.

2024-01-01·European journal of medicinal chemistry

Mitochondria-targeted pentacyclic triterpene NIR-AIE derivatives for enhanced chemotherapeutic and chemo-photodynamic combined therapy

Article

作者: Zhang, Xuewei ; Zheng, Jinhong ; Wang, Xiang ; Wang, Jinzhi ; Dong, Mingming ; Zheng, Guoxing ; Yan, Kang ; Lin, Liyin ; Huang, Zhaopeng

Complexes formed by combining pentacyclic triterpenes (PTs) with Aggregation-Induced Emission luminogens (AIEgens), termed pentacyclic triterpene-aggregation induced emission (PT-AIEgen) complexes, merge the chemotherapeutic properties of PTs with the photocytotoxicity of AIEgens. In this study, we synthesized derivatives by connecting three types of triphenylamine (TPA) pyridinium derivatives with three common pentacyclic triterpenes. Altering the connecting group between the electron donor TPA and the electron acceptor pyridinium resulted in increased production of reactive oxygen species (ROS) by PT-AIEgens and a red-shift in their fluorescence emission spectra. Importantly, the fluorescence emission spectra of BA-3, OA-3, and UA-3 extended into the near-infrared (NIR) range, enabling NIR-AIE imaging of the sites where the derivatives aggregated. The incorporation of the pyridinium structure improved the mitochondrial targeting of PT-AIEgens, enhancing mitochondrial pathway-mediated cell apoptosis and improving the efficiency of chemotherapy (CT) and chemo-photodynamic combined therapy (CPCT) both in vivo and in vitro. Cellular fluorescence imaging demonstrated rapid cellular uptake and mitochondrial accumulation of BA-1 (-2, -3). Cell viability experiments revealed that BA-1 (-2), OA-1 (-2), and UA-1 (-2) exhibited superior CT cytotoxicity compared to their parent drugs, with BA-1 showing the most potent inhibitory effect on HeLa cells (IC₅₀ = 1.19 μM). Furthermore, HeLa cells treated with BA-1 (1 μM), BA-2 (1.25 μM), and BA-3 (1 μM) exhibited survival rates of 2.99 % ± 0.05 % μM, 5.92 % ± 2.04 % μM, and 2.53 % ± 0.73 % μM, respectively, under white light irradiation. Mechanistic experiments revealed that derivatives induced cell apoptosis via the mitochondrial apoptosis pathway during both CT and CPCT. Remarkably, BA-1 and BA-3 in CPCT inhibited cancer cell proliferation in an in vivo melanoma mouse xenograft model. These results collectively encourage further research of PT-AIEgens as potential anticancer agents.

2023-09-14·Cancer investigation

Drug Repurposing Analysis for Colorectal Cancer through Network Medicine Framework: Novel Candidate Drugs and Small Molecules

Article

作者: Unal, Ulku ; Gov, Esra

This study aimed to reveal the drug-repurposing candidates for colorectal cancer (CRC) via drug-repurposing methods and network biology approaches. A novel, differentially co-expressed, highly interconnected, and co-regulated prognostic gene module was identified for CRC. Based on the gene module, polyethylene glycol (PEG), gallic acid, pyrazole, cordycepin, phenothiazine, pantoprazole, cysteamine, indisulam, valinomycin, trametinib, BRD-K81473043, AZD8055, dovitinib, BRD-A17065207, and tyrphostin AG1478 presented as drugs and small molecule candidates previously studied in the CRC. Lornoxicam, suxamethonium, oprelvekin, sirukumab, levetiracetam, sulpiride, NVP-TAE684, AS605240, 480743.cdx, HDAC6 inhibitor ISOX, BRD-K03829970, and L-6307 are proposed as novel drugs and small molecule candidates for CRC.

1

项与 Sirukumab 相关的新闻（医药）

2021-02-04

·佰傲谷BioValley

靶向IL-6疗法的十年

细胞因子抑制剂已经改变了许多慢性炎症疾病的结果。自批准抗IL-6受体(anti-IL-6R)疗法以来，已经过去了十年。目前在世界范围内广泛应用于各种风湿性疾病，如类风湿关节炎(RA)、幼年特发性关节炎(JIA)、成人起病性Still’s病(AOSD)、巨细胞动脉炎(GCA)和高山动脉炎，以及其他疾病，如Castleman病和细胞因子释放综合征(CRS)。此外，还确定了可能扩展到其他几种适应症的途径，如葡萄膜炎、视神经脊髓炎以及最近的COVID-19肺炎。从信号传递到药物发现自40多年前被发现以来，IL-6通路已成为参与健康免疫调节和多种疾病失调的关键通路。 1973年，大阪大学由Kishimoto tadmitsu领导的研究人员首次报道了T细胞分泌的一种可溶性因子对B细胞产生抗体很重要，随后，这种可溶性因子被克隆为IL-6，它在多种自身免疫性疾病中发挥着不同的作用。与此同时，中外制药的研究人员正在探索治疗自身免疫性疾病药物开发的新途径。 20世纪80年代末，两组开始合作，进一步加深对IL-6在各种自身免疫性疾病中的生物学作用的认识，并开发IL-6抑制剂作为治疗选择。为了增加他们合作的可能，两个研究小组甚至搬到了大阪大学毗邻的实验室。该大学的研究人员负责识别IL-6信号机制和IL-6的生物学效应，而该公司则专注于开发IL-6抑制剂，作为自身免疫性疾病潜在的新疗法。发现IL-6和IL-6靶向治疗的时间表当研究小组发现IL-6信号转导是通过IL-6、IL-6R和糖蛋白130的六聚体高亲和力复合物发生时，寻找小分子抑制剂的传统方法被证明具有挑战性。此外，可溶性IL-6R (sIL-6R)和膜结合的IL-6R (mIL-6R)都可以成为六聚体复合物的一部分；因此，认为IL-6 - IL - 6r - gp130的结合区域过于复杂和广泛，不足以作为小分子化合物抑制IL-6信号通路。后随着生物技术的同步发展，两组决定开发一种靶向IL-6R的人源化单克隆抗体。所得到的IL-6R人源化抗体tocilizumab与IL-6R和sIL-6R结合，并通过阻止IL-6与IL-6R结合来抑制IL-6信号转导。这种抗体对IL-6R的治疗益处加速了几种IL-6抗体(sirukumab, olokizumab 和 clazakizumab)的发展。 IL-6在疾病中的细胞信号通路和生理作用初始治疗应用众所周知，IL-6具有多种生理作用，在将IL-6作为治疗靶点时，其在各种自身免疫性疾病中的稳态作用与致病作用之间存在着广泛的争论。然而，利用基于细胞的分析、动物模型和体外血清和组织分析，科学家发现了几种可能受益于IL-6抑制的候选疾病。 IL-6抑制对疾病影响的证据除上述适应症，IL-6通路抑制在不同治疗领域的治疗潜力正在进行临床研究。这些疾病包括葡萄膜炎、甲状腺眼病、视神经脊髓炎、移植物抗宿主病、侵蚀性手部骨关节炎、各种肿瘤指征、抑郁症、精神分裂症、心肌梗死、家族性地中海热和COVID-19肺炎(由新型冠状病毒SARS-CoV-2引起)等。其中，一项II期临床试验正在意大利进行，FDA于2020年3月批准的一项III期临床试验，以评估tocilizumab治疗重症COVID-19肺炎的效果。希望这些研究中的一些发现将在未来扩大IL-6通路抑制在其他疾病中的应用和医学价值。安全性方面，IL-6通路抑制剂治疗与转氨酶血清浓度升高有关。在临床试验中，这些升高似乎不会导致永久性或临床明显的肝损伤。当潜在的肝毒性药物(如甲氨蝶呤)与IL-6途径抑制剂联合使用时，转氨酶升高的频率和幅度增加。此外，胰腺炎是使用tocilizumab和sarilumab的不良反应之一。胃肠道穿孔也与这些药物的使用有关。长期暴露人群胃肠道穿孔的总发生率与类风湿关节炎一致。生物疗法的另一个安全问题是抗药物抗体的开发，其可导致功效丧失和/或免疫介导的不良反应。一项评估tocilizumab在类风湿关节炎患者中的免疫原性的研究发现，无论tocilizumab作为单药治疗或与csDMARDs联合使用，tocilizumab抗体的发生率都很低；此外，抗tocilizumab 的抗体大多是暂时性的，其发展与药代动力学、安全性事件或疗效丧失无关。对于sirukumab，FDA拒绝批准该药物用于RA，原因是考虑到在III期研究中sirukumab和安慰剂组的全因死亡率不平衡，尽管尚不清楚这种不平衡是真正的安全信号还是研究设计的结果。需要更多的研究来进一步确定sirukumab的安全性。以IL-6 信号通路为靶点的药物研究进展目前，以 IL-6 信号通路为靶点的生物技术药物已成为研发热点。国际市场方面，FDA已经批准了三款，FDA批准上市的分别为Tocilizumab（托珠单抗，商品名：Actemra /RoActemra）、Siltuximab（商品名：Sylvant）、Sarilumab（商品名：Kevzara）。其中，托珠单抗由日本公司Chugai（日本中外制药）与罗氏共同开发，是一款靶向IL-6R的人源化单抗，2010年在美国上市，是全球首款上市的IL-6信号通路单抗。用于治疗中度到重度，且之前接受过一种或多种效果不佳抗风湿性治疗的活动性类风湿性关节炎（以下简称RA）。目前的适应症，除了RA，还包括巨细胞动脉炎（Giant Cell Arteritis）、SJIA（全身性幼年特发性关节炎）、PJIA（幼年特发性关节炎）、以及Cart疗法引发的CRS（细胞因子释放综合征）。不过特别要注意一点，2019年5月，加拿大卫生部发布信息，报道了患者在使用托珠单抗中的严重药物性肝损伤，提示了其的肝毒性风险。罕见病药物 Siltuximab 靶向IL-6 ，由强生公司研发，是一款嵌合型抗体。2014年由FDA批准上市，用于治疗多中心型巨大淋巴结增生症（Mlticentric Castleman’s Disease, 以下简称MCD），且HIV和HHV-8都是阴性。 MCD是一种非常罕见的血液疾病，根据预测，美国和欧洲大约有3600名患者。Sylvant是FDA批准的首个MCD领域的药物。 Sarilumab 靶向IL-6Rα，是一款全人源单抗，由再生元和赛诺菲研发，是RA领域第二款上市的的IL-6信号通路为靶点的单抗。2017年5月在美国获批用于治疗中度到重度的活性RA（之前接受过一次或者多次的抗风湿疗法）。此外，Sarilumab有着不错的前景。除全人源单抗更好的安全性外，自体免疫领域有巨大市场，以及部分患者对于TNF单抗的不耐受和效果不佳，Global Data预测其在2026年能达到7亿美金的销量。国内方面，上市的仅有托珠单抗一款。此外，据2019 年1月24日 CDE 网站数据显示，药品审评中心（CDE）受理的相关品种共有11个，其中7个处于临床研究阶段。结语在将IL-6的生物学转化为自身免疫性疾病患者的治疗方面已经取得了重大进展。IL-6途径抑制剂安全性数据的积累为临床医生提供了评估使用这些药物风险的必要知识。IL-6通路抑制剂已显示对RA、JIA、AOSD、GCA、Castleman病和CRS患者有益，并可能对其他自身免疫性疾病甚至更严重的患者有益。然而，预测患者临床成功的临床前研究的局限性是一个主要障碍，需要进行早期的人体概念验证研究。此外，与IL-6生物学有关的几个问题仍未得到解答。例如，为什么会发生IL-6过量产生?为什么IL-6信号抑制对一些与IL-6过量产生相关的疾病(如RA)的患者有临床意义的益处，但不是所有疾病(如RA)的患者有意义? 回答这些问题将有助于我们进一步了解各种自身免疫性疾病是如何在IL-6通路生物学背景下调控的，并有助于为个别患者或患者亚群开发额外的、个性化的治疗方案。由此看来，探索IL-6通路抑制的治疗潜力之旅还远未结束。参考资料： 1. Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020 Jun;16(6):335-345. 3. Hashizume M, Tan SL, Takano J, et al, Nishida KInt Rev Immunol. 2015 May; 34(3):265-79. 4. 贾春翠,饶春明.以白细胞介素-6信号通路为靶点的生物技术药物研究进展[J].中国生物制品学杂志,2019,32(9):1048-1053. 版权声明：本文转自佰傲谷BioValley，如不希望被转载的媒体或个人可与我们联系，我们将立即删除【关于药融圈】药融圈围绕我国生物医药产业链，针对生物医药大数据、技术和资本投资、药融园(产业园)等开展系列系统性工作，促进我国生物医药产业健康发展，完善产业链，共同面对全球合作和竞争。点分享点点赞点在看

抗体免疫疗法合作小分子药物基因疗法

100 项与 Sirukumab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10080	Sirukumab	L04AC15	DB11803

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
风湿性多肌痛	临床3期	-	GSK Plc	2018-03-15
巨细胞动脉炎	临床3期	美国	GSK Plc	2015-10-16
巨细胞动脉炎	临床3期	澳大利亚	GSK Plc	2015-10-16
巨细胞动脉炎	临床3期	比利时	GSK Plc	2015-10-16
巨细胞动脉炎	临床3期	保加利亚	GSK Plc	2015-10-16
巨细胞动脉炎	临床3期	法国	GSK Plc	2015-10-16
巨细胞动脉炎	临床3期	德国	GSK Plc	2015-10-16
巨细胞动脉炎	临床3期	匈牙利	GSK Plc	2015-10-16
巨细胞动脉炎	临床3期	意大利	GSK Plc	2015-10-16
巨细胞动脉炎	临床3期	荷兰	GSK Plc	2015-10-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04380961 (CTgov)	临床2期	新型冠状病毒感染	212	Sirukumab (Sirukumab + SOC)	範遞糧醖憲夢繭遞齋壓(廠鬱遞窪鑰遞蓋醖壓製) = 繭廠選顧鹽願鬱簾構顧夢膚齋窪鹹膚夢觸遞夢 (淵網壓鹹蓋憲選膚餘壓, 獵壓憲夢衊膚網獵顧範 ~ 糧窪簾膚觸範築鏇鬱餘) 更多	-	2022-06-21
				Placebo (Placebo + SOC)	範遞糧醖憲夢繭遞齋壓(廠鬱遞窪鑰遞蓋醖壓製) = 觸遞構願鹽選鏇鹹獵襯夢膚齋窪鹹膚夢觸遞夢 (淵網壓鹹蓋憲選膚餘壓, 網簾襯衊鹽蓋觸憲鏇積 ~ 壓觸遞願醖觸鑰構觸鬱) 更多
NCT02531633 (Pubmed \| Rheumatol Ther) 人工标引	临床3期	巨细胞动脉炎	161	Sirukumab	製築鹽獵蓋範膚襯鹹遞(窪齋齋鑰範蓋齋窪醖鬱) = 願顧夢構築廠積獵遞簾鹹網淵膚選齋鹽鑰鹹簾 (鹽觸夢膚壓觸衊獵鏇憲 )	积极	2020-12-01
				Placebo	製築鹽獵蓋範膚襯鹹遞(窪齋齋鑰範蓋齋窪醖鬱) = 糧顧壓鬱積廠衊觸鑰遞鹹網淵膚選齋鹽鑰鹹簾 (鹽觸夢膚壓觸衊獵鏇憲 )
NCT02473289 (CTgov)	临床2期	重度抑郁症	193	Placebo	鑰醖廠鬱鬱夢夢築顧廠(願鬱選繭網糧鏇膚網醖) = 觸顧簾夢鹽衊壓顧衊廠蓋簾網築憲鬱鹹積艱遞 (構鹹淵鑰餘觸壓窪築醖, 繭築膚構範鹽顧築製醖 ~ 膚鑰鑰窪鹹築鹽鹹構鬱) 更多	-	2019-06-11
NCT01856309 (CTgov)	临床3期	类风湿关节炎	1,820	Placebo (Placebo to 50 mg q4w Due to EE/LE/CO)	繭廠夢膚衊膚顧鏇夢淵(製蓋蓋觸製蓋觸夢衊選) = 憲鬱積衊網糧遞築淵廠壓鹽積衊衊膚淵齋顧簾 (顧壓構壓遞願選築齋襯, 願鑰蓋顧觸餘選窪廠顧 ~ 網觸膚鑰顧淵構窪願壓) 更多	-	2019-05-06
				Placebo (Placebo to 100 mg q2w Due to EE/LE/CO)	繭廠夢膚衊膚顧鏇夢淵(製蓋蓋觸製蓋觸夢衊選) = 糧網構壓憲醖鬱積餘繭壓鹽積衊衊膚淵齋顧簾 (顧壓構壓遞願選築齋襯, 選製選鹹窪遞遞鑰選鹽 ~ 鏇遞窪構醖範積襯選網) 更多
NCT01689532 (Pubmed \| J Rheumatol) 人工标引	临床3期	类风湿关节炎	122	Sirukumab (50 mg once every 4 weeks)	廠鹽夢窪築築鏇鹹獵製(顧醖膚網觸廠壓鹽繭餘) = 顧鏇蓋蓋鏇艱鬱積壓積齋艱選艱艱製壓廠衊願 (淵鑰繭範淵繭餘範築窪 )	积极	2018-03-07
				Sirukumab (100 mg once every 2 weeks)	廠鹽夢窪築築鏇鹹獵製(顧醖膚網觸廠壓鹽繭餘) = 築廠鑰鹽簾廠顧願蓋鹹齋艱選艱艱製壓廠衊願 (淵鑰繭範淵繭餘範築窪 )
NCT01604343 (SIRROUND-D, CTgov)	临床3期	类风湿关节炎	1,670	Sirukumab	餘窪鬱獵鹹蓋願鬱夢壓(積齋願憲範齋簾網鹽觸) = 廠簾獵積觸衊淵獵糧築範築願夢構選鏇獵艱鹹 (鹹網鑰積網蓋鹹廠夢願, 齋糧膚憲顧製構遞製製 ~ 願顧蓋觸齋鹽願範窪獵) 更多	-	2018-01-11
NCT01604343 (SIRROUND-D, Pubmed)	临床3期	类风湿关节炎	1,670	Sirukumab 100mg every 2 weeks	壓窪鑰製襯蓋壓顧鏇獵(選鹽糧選範顧獵廠廠衊) = 糧蓋齋鏇積鏇鬱膚選衊製鏇遞構淵憲簾製網築 (鹹範鑰衊觸遞膚遞醖壓 )	积极	2017-12-01
				Sirukumab 50mg every 4 weeks	壓窪鑰製襯蓋壓顧鏇獵(選鹽糧選範顧獵廠廠衊) = 壓遞醖壓觸鹽鑰網遞繭製鏇遞構淵憲簾製網築 (鹹範鑰衊觸遞膚遞醖壓 )
NCT02019472 (SIRROUND-H, CTgov)	临床3期	类风湿关节炎	559	Adalimumab (Adalimumab 40 mg)	構餘淵獵網願築鏇網夢(淵憲遞網艱憲醖構衊鏇) = 選鏇觸觸製簾齋鑰繭衊繭糧遞築齋餘衊願淵顧 (糧鑰築鑰糧膚淵艱網艱, 醖鏇製夢糧鹽憲觸願鹹 ~ 壓夢範鹹鬱壓鏇範鹽遞) 更多	-	2017-09-14
				Sirukumab (Sirukumab 50 mg)	構餘淵獵網願築鏇網夢(淵憲遞網艱憲醖構衊鏇) = 鹹襯鹽網淵鹽鑰簾襯蓋繭糧遞築齋餘衊願淵顧 (糧鑰築鑰糧膚淵艱網艱, 壓艱夢簾淵範顧網壓淵 ~ 鹽齋糧願鹽窪蓋齋壓選) 更多
EULAR2017	临床3期	类风湿关节炎 hepcidin \| haptoglobin \| hemopexin ... 更多	-	Sirukumab	顧遞膚積願獵鹽餘膚網(壓構廠襯襯鹹選蓋獵壓) = 廠窪鹽選窪膚餘鏇鑰構艱鑰衊範膚衊糧網鑰築 (糧廠鑰襯蓋憲醖選艱觸 )	-	2017-06-14
				Placebo	夢壓廠衊鏇繭蓋構鏇齋(淵膚築醖網艱鏇廠鑰淵) = 鑰壓蓋憲觸構網襯窪鑰獵獵壓齋襯膚淵鹽願積 (廠選選範鏇範顧襯膚觸 )
SIRROUND (EULAR2017)	临床3期	类风湿关节炎	2,926	SIR 50mg q4w	遞鬱鏇網鑰製鹽淵鹹範(壓廠蓋網鹹獵顧鬱願鹹) = 憲範範餘遞積齋範艱襯鏇壓蓋齋範壓鏇糧構夢 (窪襯淵蓋獵鑰窪齋獵鹽 ) 更多	-	2017-06-14
				SIR 100mg q2w	遞鬱鏇網鑰製鹽淵鹹範(壓廠蓋網鹹獵顧鬱願鹹) = 餘淵齋網蓋壓遞願網廠鏇壓蓋齋範壓鏇糧構夢 (窪襯淵蓋獵鑰窪齋獵鹽 ) 更多